Edition:
United States

GlaxoSmithKline PLC (GSK)

GSK on New York Consolidated

42.41USD
28 Mar 2017
Change (% chg)

$-0.28 (-0.66%)
Prev Close
$42.69
Open
$42.61
Day's High
$42.67
Day's Low
$42.37
Volume
1,911,795
Avg. Vol
3,584,798
52-wk High
$45.58
52-wk Low
$37.20

Latest Key Developments (Source: Significant Developments)

GSK announces U.S. regulatory submission seeking expanded indication for Fluarix Quadrivalent for infants 6 months and older
Wednesday, 15 Mar 2017 11:13am EDT 

Glaxosmithkline Plc :GSK announces US regulatory submission seeking expanded indication for Fluarix Quadrivalent (Influenza vaccine) for infants 6 months and older.  Full Article

GSK says asthma drug Nucala (Mepolizumab) meets primary endpoints
Monday, 6 Mar 2017 09:49am EST 

GlaxoSmithKline Plc : Phase IIIB Musca study successfully met all its primary and secondary endpoints . Patients treated with Nucala (Mepolizumab) achieved clinically and statistically significant improvements in quality of life and lung function versus placebo . St. Georges respiratory questionnaire improved by 7.7 units from baseline versus. Placebo (p=0.001) . Lung function (first secondary endpoint), as measured by pre-bronchodilator fev1, increased by 120ml (p=0.001) more than in placebo patients . Asthma control showed a significant improvement versus. Placebo in Mepolizumab treatment group by 0.40 units (p<0.001) .Safety profile of Mepolizumab in Musca study was consistent with product label for Nucala.  Full Article

GSK submits regulatory application in Japan for belimumab
Tuesday, 13 Dec 2016 04:21am EST 

GlaxoSmithKline Plc : Submits regulatory application in Japan for belimumab in systemic lupus erythematosus Further company coverage: [GSK.L] (Bengaluru Newsroom) ((+91 806 749 1136;)).  Full Article

Fimbrion, GSK to develop novel antibacterial therapy for UTIs
Tuesday, 25 Oct 2016 09:45am EDT 

Fimbrion Therapeutics Inc:Fimbrion - co and GSK to develop novel antibacterial therapy for urinary tract infections.  Full Article

Glaxo to pay $20 mln to resolve SEC charges
Friday, 30 Sep 2016 02:15pm EDT 

GlaxoSmithKline PLC : SEC says GlaxoSmithKline PLC to pay $20 million to settle foreign corrupt practices act charges . SEC says civil penalty resolves charges that glaxo's China-based units engaged in pay-to-prescribe schemes to boost sales . SEC says glaxo did not admit or deny wrongdoing . SEC says glaxo's accounting controls failed to prevent schemes, and improper payments were not accurately reflected in its books.  Full Article

GlaxoSmithKline appoints new consumer healthcare CEO
Thursday, 29 Sep 2016 07:40am EDT 

GlaxoSmithKline Plc : GlaxoSmithKline plc appoints Brian McNamara as CEO of GSK consumer healthcare . McNamara succeeds Emma Walmsley who was last week appointed GSK CEO designate succeeding Sir Andrew Witty as GSK CEO . McNamara is currently head of Europe & Americas at GSK consumer healthcare Further company coverage: [GSK.L] (Bengaluru Newsroom) ((+91 806 749 1136;)).  Full Article

Aspen Pharmacare says GSK sells remaining stake in co
Thursday, 29 Sep 2016 03:05am EDT 

Aspen Pharmacare Holdings Ltd : GSK completed an accelerated bookbuild for disposal of its remaining shareholding in aspen .Disposal in no way affects ongoing collaboration between aspen and GSK in South Africa.  Full Article

GSK gets 477 mln stg gross proceeds from Aspen Pharmacare stake sale
Thursday, 29 Sep 2016 02:54am EDT 

Glaxosmithkline Plc :Gross proceeds of Aspen transaction are equivalent to £477 million.  Full Article

GSK says to sell remaining stake in Aspen Pharmacare
Wednesday, 28 Sep 2016 11:19am EDT 

GlaxoSmithKline Plc : GSK intends to sell remaining holding in Aspen . Intends to sell its remaining stake in Aspen Pharmacare Holdings Ltd . Offer price will be determined by means of an accelerated bookbuild offering process which is to start immediately .Offering is expected to comprise up to 28.2 million Aspen ordinary shares equivalent to 6.2 pct of Aspen's ordinary share capital.  Full Article

GSK, Oncodesign announce agreement for Oncodesign's Acquisition of GSK's Research Centre in France
Wednesday, 28 Sep 2016 01:30am EDT 

Oncodesign SA : Says GSK will provide EUR35 million support over a four year period . To use funding to integrate site, its capabilities into its business and ensure continued employment of transferring staff over the period .GSK, Oncodesign announce agreement for Oncodesign's acquisition of GSK's research centre in France.  Full Article

More From Around the Web

BRIEF-GSK announces U.S. regulatory submission seeking expanded indication for Fluarix Quadrivalent for infants 6 months and older

* GSK announces US regulatory submission seeking expanded indication for Fluarix Quadrivalent (Influenza vaccine) for infants 6 months and older Source text for Eikon: Further company coverage: